DB:8NE2

Stock Analysis Report

Executive Summary

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia.


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has Caladrius Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8NE2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-21.4%

8NE2

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-32.7%

8NE2

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 8NE2 underperformed the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 8NE2 underperformed the German Market which returned 2.9% over the past year.


Shareholder returns

8NE2IndustryMarket
7 Day-21.4%-11.1%-9.1%
30 Day-15.6%-12.8%-7.2%
90 Day-3.4%-9.6%-6.5%
1 Year-32.7%-32.7%-2.7%-2.9%6.1%2.9%
3 Year-52.2%-52.2%25.8%24.4%3.5%-5.6%
5 Year-93.5%-93.5%1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Caladrius Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Caladrius Biosciences undervalued compared to its fair value and its price relative to the market?

1.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8NE2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8NE2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8NE2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 8NE2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8NE2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8NE2 is good value based on its PB Ratio (1.1x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Caladrius Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8NE2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8NE2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8NE2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8NE2's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 8NE2's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8NE2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Caladrius Biosciences performed over the past 5 years?

33.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8NE2 is currently unprofitable.

Growing Profit Margin: 8NE2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8NE2 is unprofitable, but has reduced losses over the past 5 years at a rate of 33.9% per year.

Accelerating Growth: Unable to compare 8NE2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8NE2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 8NE2 has a negative Return on Equity (-71.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Caladrius Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 8NE2's short term assets ($30.2M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: 8NE2's short term assets ($30.2M) exceed its long term liabilities ($710.0K).


Debt to Equity History and Analysis

Debt Level: 8NE2 is debt free.

Reducing Debt: 8NE2 has no debt compared to 5 years ago when its debt to equity ratio was 26.5%.


Balance Sheet

Inventory Level: 8NE2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 8NE2's debt is covered by short term assets (assets are 1.3620686713019E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8NE2 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 8NE2 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Caladrius Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 8NE2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8NE2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8NE2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8NE2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8NE2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Dave Mazzo (62yo)

5.1yrs

Tenure

US$1,892,243

Compensation

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. serves as Lead Independent Director at Neuralstem, Inc. since 2019. Dr. Mazzo has been the Chief Executive Officer of Caladr ...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD1.89M) is above average for companies of similar size in the German market ($USD419.45K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
David Mazzo
President5.1yrsUS$1.89m1.79% $432.2k
Joseph Talamo
CFO & Senior VP4.3yrsUS$834.96k0.57% $138.3k
Douglas Losordo
Executive VP6.5yrsUS$1.01m1.25% $302.4k
John Menditto
Vice President of Investor Relations & Corporate Communications2.2yrsno datano data
Todd Girolamo
Senior VP4.3yrsno datano data
Eric Powers
Director of Communications and Marketing0yrsno datano data
Gail Holler
Vice President of Human Resources1.1yrsno datano data
Ian Zhang
President of NeoStem (China)9.4yrsno datano data

4.3yrs

Average Tenure

57yo

Average Age

Experienced Management: 8NE2's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Mazzo
President5.1yrsUS$1.89m1.79% $432.2k
Steven Klosk
Independent Director5.6yrsUS$97.65k0.26% $63.5k
Steven Myers
Independent Director13.3yrsUS$96.15k0.63% $152.2k
Gregory Brown
Independent Chairman of the Board3yrsUS$136.15k0.040% $9.6k
Peter Traber
Independent Director5.1yrsUS$92.65k0.24% $58.4k
Robert Negrin
Immune Modulation Program Advisor0yrsno datano data
Robert Korngold
Immune Modulation Program Advisor0yrsno datano data
David Horwitz
Immune Modulation Program Advisor0yrsno datano data
David Peritt
Immune Modulation Program Advisor0yrsno datano data
Noel Warner
Immune Modulation Program Advisor0yrsno datano data

5.1yrs

Average Tenure

64yo

Average Age

Experienced Board: 8NE2's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.


Top Shareholders

Company Information

Caladrius Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Caladrius Biosciences, Inc.
  • Ticker: 8NE2
  • Exchange: DB
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$26.520m
  • Listing Market Cap: US$24.114m
  • Shares outstanding: 10.40m
  • Website: https://www.caladrius.com

Number of Employees


Location

  • Caladrius Biosciences, Inc.
  • 110 Allen Road
  • 2nd Floor
  • Basking Ridge
  • New Jersey
  • 7920
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLBSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 1981
8NE2DB (Deutsche Boerse AG)YesCommon StockDEEURApr 1981
0HS8LSE (London Stock Exchange)YesCommon StockGBUSDApr 1981
8NE2BRSE (Berne Stock Exchange)YesCommon StockCHCHFApr 1981

Biography

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 that is in Phase II clinical trial for the treatment of critical limb ischemia; CLBS14-CMD, which is in Phase II clinical study to treat coronary microvascular dysfunction; and CLBS14-NORDA that is in Phase III clinical trial for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 21:45
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.